79 related articles for article (PubMed ID: 9489823)
1. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis.
Seibold JR; Clements PJ; Furst DE; Mayes MD; McCloskey DA; Moreland LW; White B; Wigley FM; Rocco S; Erikson M; Hannigan JF; Sanders ME; Amento EP
J Rheumatol; 1998 Feb; 25(2):302-7. PubMed ID: 9489823
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
Seibold JR; Korn JH; Simms R; Clements PJ; Moreland LW; Mayes MD; Furst DE; Rothfield N; Steen V; Weisman M; Collier D; Wigley FM; Merkel PA; Csuka ME; Hsu V; Rocco S; Erikson M; Hannigan J; Harkonen WS; Sanders ME
Ann Intern Med; 2000 Jun; 132(11):871-9. PubMed ID: 10836913
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Khanna D; Clements PJ; Furst DE; Korn JH; Ellman M; Rothfield N; Wigley FM; Moreland LW; Silver R; Kim YH; Steen VD; Firestein GS; Kavanaugh AF; Weisman M; Mayes MD; Collier D; Csuka ME; Simms R; Merkel PA; Medsger TA; Sanders ME; Maranian P; Seibold JR;
Arthritis Rheum; 2009 Apr; 60(4):1102-11. PubMed ID: 19333948
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening.
Bell RJ; Permezel M; MacLennan A; Hughes C; Healy D; Brennecke S
Obstet Gynecol; 1993 Sep; 82(3):328-33. PubMed ID: 8355929
[TBL] [Abstract][Full Text] [Related]
5. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
[TBL] [Abstract][Full Text] [Related]
6. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
Genovese MC; Chakravarty EF; Boyle DL; Tutuncu Z; Thorburn CM; Halilhodzic M; Kroll S; Baughman J; Stewart S; Kavanaugh A
J Rheumatol; 2005 Dec; 32(12):2345-50. PubMed ID: 16331761
[TBL] [Abstract][Full Text] [Related]
7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
9. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
10. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.
Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
J Card Fail; 2009 Apr; 15(3):182-90. PubMed ID: 19327619
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
15. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
18. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
